Pramiracetam

Overview

Pramiracetam is a non-peptide synthetic racetam-class nootropic (2-oxopyrrolidone/pyrrolidinone acetamide derivative) with CAS 68497-62-1 and molecular formula C14H27N3O2. It was previously approved and marketed in Italy and some Eastern European countries under brand names Pramistar, Neupramir, and Remen for memory/attention deficits in aging-associated dementias; Italian authorization was revoked in 2020 at manufacturer request. It is not FDA-approved in the United States, where it is sold only as an unapproved gray-market research chemical. The related racetam phenylpiracetam is explicitly listed on the WADA Prohibited List as an S6 stimulant; pramiracetam itself is not explicitly named, leaving its status under WADA's 'similar structure/effect' catch-all unresolved.

Mechanism of Action

Proposed mechanism is based on animal/in-vitro data, not confirmed in humans: pramiracetam significantly increased sodium-dependent high-affinity choline uptake (HACU) into rat hippocampal synaptosomes in vitro, an effect specific to hippocampus (not observed in cerebral cortex or corpus striatum). At 100 mg/kg i.p. it did not alter norepinephrine, dopamine, serotonin, 5-HIAA, or HVA levels in rat brain, suggesting the effect is not mediated via direct monoaminergic action. The hypothesized downstream effect is increased availability of choline as an acetylcholine synthesis precursor in cholinergic terminals; a separate rat study found systemic pramiracetam increased cortical (not hippocampal) nitric oxide synthase activity in a dose-dependent manner.

Research Summary

Human data consist of a handful of small older trials (1985–1996): healthy-volunteer pharmacokinetic studies, a scopolamine-induced-amnesia challenge study, a placebo-controlled trial in young males with head-injury/anoxia-related memory deficits (400 mg TID improved delayed recall), and a small dose-finding trial in Alzheimer's disease that found no convincing benefit at doses up to 4,000 mg. A scopolamine-challenge study (600 mg BID × 10 days) showed partial mitigation of induced amnesia in healthy young and older male volunteers. No modern (post-2000) randomized controlled trials were located. Preclinical findings: in rats, 7.5 and 15 mg/kg/day × 7 weeks significantly improved reference (long-term) memory on a 16-arm radial maze but did not affect working memory; 300 mg/kg i.p. increased cortical nitric oxide synthase activity ~20% (synergistic ~40% increase with lithium pretreatment); moderate protection against hypobaric-hypoxia-induced deficits in immature rats.

Reported Side Effects

• No dedicated human toxicology (LD50/acute overdose) data located
• Reviewed human trials did not report serious adverse events in abstracts (full safety data not independently verified)
• Related racetam phenylpiracetam is WADA-prohibited; pramiracetam's status under 'similar structure/effect' catch-all is unresolved
• Drug-drug interaction profile unestablished
• Pregnancy/lactation safety data not found

Compare Pramiracetam with Others

Research References

• Some neurochemical properties of pramiracetam (CI-879), a new cognition-enhancing agent. 1983.
• The effect of pramiracetam (CI-879) on the acquisition of a radial arm maze task. 1986. PMID 3088666.
• Pharmacokinetics of oral pramiracetam in normal volunteers. 1985. PMID 4008675.
• Pharmacokinetics of pramiracetam in healthy volunteers after oral administration. 1992. PMID 1473879.

Frequently asked questions

Has Pramiracetam been independently lab-tested?

Disclosed Labs has collected 2 Certificates of Analysis (COA) for Pramiracetam from 2 independent testing labs. 1 vendor has submitted material for testing. Products average 99.9% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/pramiracetam/testing.

How does Pramiracetam work?

Proposed mechanism is based on animal/in-vitro data, not confirmed in humans: pramiracetam significantly increased sodium-dependent high-affinity choline uptake (HACU) into rat hippocampal synaptosomes in vitro, an effect specific to hippocampus (not observed in cerebral cortex or corpus striatum). At 100 mg/kg i.p. it did not alter norepinephrine, dopamine, serotonin, 5-HIAA, or HVA levels in rat brain, suggesting the effect is not mediated via direct monoaminergic action. The hypothesized downstream effect is increased availability of choline as an acetylcholine synthesis precursor in cholinergic terminals; a separate rat study found systemic pramiracetam increased cortical (not hippocampal) nitric oxide synthase activity in a dose-dependent manner.

What does the research say about Pramiracetam?

Human data consist of a handful of small older trials (1985–1996): healthy-volunteer pharmacokinetic studies, a scopolamine-induced-amnesia challenge study, a placebo-controlled trial in young males with head-injury/anoxia-related memory deficits (400 mg TID improved delayed recall), and a small dose-finding trial in Alzheimer's disease that found no convincing benefit at doses up to 4,000 mg. A scopolamine-challenge study (600 mg BID × 10 days) showed partial mitigation of induced amnesia in healthy young and older male volunteers. No modern (post-2000) randomized controlled trials were located. Preclinical findings: in rats, 7.5 and 15 mg/kg/day × 7 weeks significantly improved reference (long-term) memory on a 16-arm radial maze but did not affect working memory; 300 mg/kg i.p. increased cortical nitric oxide synthase activity ~20% (synergistic ~40% increase with lithium pretreatment); moderate protection against hypobaric-hypoxia-induced deficits in immature rats.